Logo

Calando Pharmaceuticals, new Arrowhead Subsidiary, to Commercialize Therapeutic RNAi Delivery Technologies

Feb 22, 2005

NEW YORK, Feb. 22 (GenomeWeb News) - Arrowhead Research has formed a new subsidiary, Calando Pharmaceuticals, which plans to commercialize technologies for the therapeutic use of RNA interference, the Pasadena, Calif.-based company said today.

 

Calando, majority-owned by nanotechnology company Arrowhead, intends to develop non-viral RNAi delivery technologies licensed from the California Institute of Technology for therapeutic purposes. Caltech will receive an equity stake in exchange for the license.

 

Apart from Arrowhead, founders of Calando include Mark Davis, a professor of chemical engineering at Caltech; John Rossi, a molecular geneticist at the City of Hope's Beckman Research Institute; Matt Vincent, a partner of law firm Ropes & Gray; and John Petrovich, who will be Calando's CEO.

Breaking News
The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.